Codice QR

Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO

Abstract: Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains challenging to treat, especially in patients ineligible for intensive therapy or chimeric antigen receptor T cells. Tafasitamab plus lenalidomide (T/L) is an effective option based on the phase 2 L-MIND trial findings, a...

Descrizione completa

Salvato in:
Autori principali: Antonio Gutierrez, Izaskun Zeberio, Francisco Javier Peñalver, Pilar Martinez-Barranco, Sandra Perez, Daniel Morillo, Xabier Martin, Concepcion Nicolas, Ainara Ferrero, Ana Jimenez-Ubieto, Mariana Bastos-Oreiro, Julio Davila-Valls, Maria Victoria Calle, María Perez, Guillermo Rodriguez, Aranzazu Alonso, Ana Garcia-Noblejas, Diana Sanchez Argüello, Teresa Knight, Ángeles Fernandez, Javier Lopez, Jaime Perez De Oteyza, Sonia González de Villambrosia, Elena Perez, Alejandro Marin, Maria Belen Navarro, Ruben Fernandez, Pilar Gomez, José Antonio Hueso, Maria Jesus Peñarrubia Ponce, Pilar Bravo, Daniel Garcia-Belmonte, Haridian De La Nuez, Sara Nistal, Pau Abrisqueta, Fernanda Ibañez, Luis Palomera, Eva Donato, Andrea Provencio, Maria Stefania Infante, Eva Gonzalez-Barca
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2025-10-01
Serie:Blood Advances
Accesso online:http://www.sciencedirect.com/science/article/pii/S2473952925004094
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi